Prostat taşları ve prostat kanseri: İlişki var mı?

Bu çalışmada prostat taşlan ile prostat kanserinin birlikteliği araştırılmıştır. Temmuz 2004 ile mart 2005 tarihleri arasında transrektal ultrasonografı (TRUS) eşliğinde 6 kor prostat biyopsisi yapılan 141 hasta çalışmaya alınmıştır. Hastaların tamamında; serum PSA düzeyinin 4 ng/ml'nin üzerinde olması ye/veya parmakla rektal muayenedeki (PRM) anormal bulgular nedeniyle prostat kanseri şüphesi bulunmaktaydı. Hastalar serum PSA düzeylerine göre üç gruba ayrılarak değerlendirildiler. (Sırasıyla PSA < 10 ng/ml, PSA 10-20 ng/ml, and PSA > 20 ng/ml) Yetmiş altı hastada (%53.9) prostat taşı saptandı. 141 hastanın 29'unda (%20.6) pozitif prostat biyopsisi gözlendi. Benign prostat hiperplazili (BPH) ve prostat kanserli hasta grupları arasında prostat taşı görülmesi açısından istatistiksel olarak anlamlı bir fark saptanmadı. (Sırasıyla %54.9, %51.7; p=0.56) Serum PSA düzeyi 10 ng/ml'nin altında olan ve prostat kanseri saptanan hastalar BPH'li hastalarla karşılaştırıldığında, bu grupta prostat taşları nispeten daha yüksek olarak gözlenmekle birlikte bu bulgu istatistiksel olarak anlamlı değildi. (Sırasıyla %83.33, %59.3; p=0.2).Bu çalışmada prostat taşları ve prostat kanserinin birlikte görülmeleri açısından istatistiksel olarak anlamlı bir fark bulunmamıştır. Prostat taşları BPH'li ve prostat kanserli hastalarda benzer dağılım göstermektedir.

Prostatic calculi and prostate cancer: Is there an association

Retrospectively, we investigated the association of prostatic calculi with prostate cancer. Between July 2004 and March 2005, 141 patients who underwent sextant core transrectal ultrasound (TRUS) guided prostate biopsy were enrolled. All patients had a suspicion of prostate cancer in the form of prostate specific antigen (PSA) > 4 ng/ml and/or abnormal digital rectal examination (DRE). The patients were divided into three groups according to their PSA values (PSA < 10 ng/ml, PSA 10-20 ng/ml, and PSA > 20 ng/ml respectively) and were evaluated separately. Prostatic calculi were detected in 76 patients (53.9 %). Out of 141 patients, 29 had positive prostate biopsy (20.6%). No significant difference was found between the presence of prostatic calculi in patients with benign prostatic hyperplasia (BPH) and prostate cancer (54.9%, 51.7% respectively; P = 0.56). Patients with prostate cancer and PSA < 10 ng/ml were associated with statistically insignificant higher incidence of prostate calculi compared to patients with BPH in the same group (83.33%, 59.3% respectively; p = 0.2). There is no association between the presence of prostatic calculi and prostate cancer. The prostatic calculi show similar distribution between patients with BPH and prostate cancer.

Kaynakça

1.Gardner WA,Jr.Bennett BD.:The prostate overview: recent insights and speradutions.In pathology and pathobiology of the urinary bladder and Prostate. Edited by RS Weinstein and WA. Gardner, Jr.Baltimore: Williams and Wilkens Co., pp. 129-148, 1992.

2.Nelson WG, De Marz AM,Isaacs WB.: Prostate cancer. NEngle J Med, 349(4): 366-81, 2003.

3.Coleman WB: Mechanisim of human hepatocarcinogenesis. Curr Mol Med, 3:573, 2003

4.Sutor, DJ. and Wooley S.: The crystalline composition of prostatic calculi. BrJUrol, 46: 533, 1974.

5.Torres Ramerez C, Aguilar Ruiz J, Zuluaga Gomez A, Espuela Orgaz R. and Del Rio Samper, S.: A crystallographic study of prostate calculi. J Urol, 124;840,1980

6.Terris MK. and Stamey TA.: Determination of prostate volume by transrectal ultrasound. J Urol, 145:984,1991.

7.Landis SH, Muray T, Bolden S et al: Cancer statistics. 1998 [published errata appear in Ca cancer J Clin 1998; 48:192 and 1998; 48:329]. Ca cancer J Clin,, 48:6, 1998.

8.Landis SH, Muray T, Bolden S et al: Cancer statistics 1999. Ca Cancer J Clin, 49: 8, 1999.

9.Mc Crede M, Coates M, Grulich A.: Cancer incidence in migrant to New South Wales (Autralia) from the middle east, 1972-91. Cancer Causes Control; 5(5): 414-21, 1994.

10.Boyle P, Maisonneuve P, Napalkov P.: Geographical and temporal pattern of incidence and mortality of prostate cancer. Urology, 46: 47-55, 1995.

11.SAMASO Cancer Program Annual Report, 2001.

12.Tandon P, Pathak VP, Zaheer A et al: Cancer in Gizan province of Saudi Arabia: an eleven year study. Ann Saudi Med Jan, 15(1): 14-20, 1995.

13.Sondergaard G, Venter M. and Christensen PO.: Prostatic calculi. Ada Pathol Microbiol Immunol ) 95: 141, 1987.

14.Ludwig M, Weidner W, Schroeder-Printzen I et al: Transrectal prostatic sonography as a useful diagnostic means for patients with chronic prostatitis or prostatodynia. BrJUrol, 73: 664, 1994.

15.Sang EL, Ja HK, Hyoung KP et al,: Prostatic calculi don't influence the level of serum prostate-sepecific antigen in men without clinically detectable prostate cancer or prostatitis. J Urol, 170: 745-748, 2003.

16.De Merzo AM, Marchi VL, Epstein JI et al: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Path, 155; 1985, 1999.

17.Parsons JK, Nelson CP, Gage WR et al: GSTAI expression in the normal, preneoplastic and neoplastic human prostate tissue. Prostate, 49: 30, 2001.

18.Lee WH, Morton RA, Epstein JI et al: Cytidine methylation of regulatory sequences near the p-class gİutathione S- transferase gene accompanies human prostatic carcinogenesis. Proc Nat! Acad Sci, 91: 11733,1994.

19.Brook JD, Weinstein M, Lin X et al: CG island methylation changes near to the GSTPI gene in prostatic intraepithelial neoplasia. Cancer Epedimiol Biomarkers Prev, 7: 531, 1998.

Kaynak Göster